Top broker tips Australian Clinical Labs (ASX:ACL) share price to shoot higher

This broker thinks ASX investors should get better acquainted with this ASX share…

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian Clinical Labs Ltd (ASX: ACL) share price is pushing higher on Monday.

In afternoon trade, the pathology services provider's shares are up 2% to $3.76.

Despite this gain, the Australian Clinical Labs share price is still trading 6% below its May IPO price of $4.00.

Why is the Australian Clinical Labs share price pushing higher?

Investors have been buying the company's shares this morning following the release of a bullish broker note out of Goldman Sachs.

According to the note, the broker has initiated coverage on the company with a buy rating and $4.80 price target. Based on the current Australian Clinical Labs share price, this implies potential upside of almost 28% over the next 12 months.

Goldman Sachs was the joint lead manager and underwriter of the company's IPO last month.

What did Goldman Sachs say?

Goldman believes that Australian Clinical Labs will benefit from a series of operational investments. These include its unified Laboratory Information System and upgraded central laboratory network.

In addition to this, over the long term, the broker expects the company's growth to track around market growth of 3% to 5%. However, it sees scope for the company to achieve the upper end of this range if it executes well on growth strategies in New South Wales and Queensland.

Furthermore, it notes that with leverage of 1.0x net debt/EBITDA, there is the opportunity to accelerate its growth through acquisitions.

Attractive valuation

Another reason to be positive on the Australian Clinical Labs share price is its valuation. Particularly in comparison to rivals Healius Ltd (ASX: HLS) and Sonic Healthcare Limited (ASX: SHL).

Goldman commented: "We believe current trading multiples are undemanding: FY22E EV/EBITDA 6.8x (vs. HLS 9.1x; SHL 11.3x) and FY22E EV/EBIT: 16.2x (vs. HLS 20.1x; SHL 17.6x)."

"Whilst the forward EBIT growth profile of +4% (FY22-25E) is less attractive than HLS (+7%), it is above SHL (+2%), and hence in-line with the peer average. ASX 200 HC [healthcare sector] trades on 21x EBITDA for +8% CAGR," it added.

This could make it worth considering if you're looking for healthcare options.

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Opinions

Too high? These 2 ASX shares might be due for a correction

These popular blue chips are looking dicey to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Why Clarity, Coronado Global, Iperionx, and Lynas shares are roaring higher today

These shares are having a strong session on Thursday. Why are investors buying them?

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Opinions

The ASX 200 is approaching its all-time high. Here's why I'm not buying shares

I'm not seeing what the broader market is.

Read more »